MX2015012215A - Nuevos polipeptidos. - Google Patents

Nuevos polipeptidos.

Info

Publication number
MX2015012215A
MX2015012215A MX2015012215A MX2015012215A MX2015012215A MX 2015012215 A MX2015012215 A MX 2015012215A MX 2015012215 A MX2015012215 A MX 2015012215A MX 2015012215 A MX2015012215 A MX 2015012215A MX 2015012215 A MX2015012215 A MX 2015012215A
Authority
MX
Mexico
Prior art keywords
fcrn
present disclosure
binding polypeptide
new polypeptides
relates
Prior art date
Application number
MX2015012215A
Other languages
English (en)
Other versions
MX366425B (es
Inventor
Caroline Ekblad
Lars Abrahmsén
Malin Lindborg
Elin Gunneriusson
John Löfblom
Torbjörn Gräslund
Johan Seijsing
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody Ab filed Critical Affibody Ab
Publication of MX2015012215A publication Critical patent/MX2015012215A/es
Publication of MX366425B publication Critical patent/MX366425B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)

Abstract

La presente exposición se refiere a una clase de polipéptidos diseñados que tienen una actividad de enlace para el receptor neonatal Fc (en lo siguiente referido como FcRn) y proporciona un polipéptido de enlace a FcRn que comprende la secuencia EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29. La presente exposición se refiere también al uso de tal polipéptido de enlace a FcRn como un agente para modificar las propiedades farmacocinéticas y farmacodinámicas y como un agente terapéutico.
MX2015012215A 2013-03-15 2014-03-17 Nuevos polipeptidos. MX366425B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361787305P 2013-03-15 2013-03-15
EP13159500 2013-03-15
PCT/EP2014/055299 WO2014140366A1 (en) 2013-03-15 2014-03-17 New polypeptides

Publications (2)

Publication Number Publication Date
MX2015012215A true MX2015012215A (es) 2016-05-16
MX366425B MX366425B (es) 2019-07-04

Family

ID=47891491

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012215A MX366425B (es) 2013-03-15 2014-03-17 Nuevos polipeptidos.

Country Status (17)

Country Link
US (3) US9975943B2 (es)
EP (1) EP2970406B1 (es)
JP (1) JP6608288B2 (es)
KR (1) KR102191654B1 (es)
CN (1) CN105209482B (es)
AU (1) AU2014230018B2 (es)
BR (1) BR112015021730A2 (es)
CA (1) CA2902657C (es)
DK (1) DK2970406T3 (es)
ES (1) ES2660912T3 (es)
HK (1) HK1216756A1 (es)
IL (1) IL240606B (es)
LT (1) LT2970406T (es)
MX (1) MX366425B (es)
MY (1) MY171407A (es)
RU (1) RU2681428C2 (es)
WO (1) WO2014140366A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
EP2762493B1 (en) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
JP6276202B2 (ja) 2012-02-20 2018-02-07 スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） ヒト補体ｃ５に結合するポリペプチド
NZ705370A (en) 2012-08-24 2018-06-29 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
BR112015021730A2 (pt) 2013-03-15 2017-08-29 Affibody Ab POLIPEPTÍDEO DE LIGAÇÃO AO FcRn, PROTEÍNA DE FUSÃO OU CONJUGADO, POLINUCLEOTÍDEO QUE CODIFICA UM POLIPEPTÍDEO, COMPOSIÇÃO, POLIPEPTÍDEO DE LIGAÇÃO AO FcRn, PROTEÍNA DE FUSÃO OU CONJUGADO E POLIPEPTÍDEO DE LIGAÇÃO AO FcRn, PROTEÍNA DE FUSÃO, CONJUGADO OU COMPOSIÇÃO PARA USO
ZA201506407B (en) * 2013-03-15 2018-11-28 Affibody Ab New polypeptides
KR102318483B1 (ko) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
MX2017003459A (es) * 2014-09-17 2017-10-31 Affibody Ab Polipeptidos novedosos.
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
DK3245224T3 (da) * 2015-01-12 2020-09-21 Affibody Ab Il-17a-bindende polypeptider
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
MX2018005399A (es) * 2015-10-30 2018-06-06 Affibody Ab Nuevo polipeptido con afinidad por pd-l1.
JP6990652B2 (ja) 2015-10-30 2022-02-03 アフィボディ・アーベー 新規ポリペプチド
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
KR20210018928A (ko) 2018-06-08 2021-02-18 아르제넥스 비브이비에이 면역성 혈소판 감소증을 치료하기 위한 조성물 및 방법
US20210340257A1 (en) * 2018-08-23 2021-11-04 Lotfi Abou-Elkacem Affibody proteins specific for b7-h3 (cd276)
WO2021089695A1 (en) * 2019-11-05 2021-05-14 Affibody Ab Polypeptides
WO2023141360A2 (en) * 2022-01-24 2023-07-27 Regents Of The University Of Minnesota Anti-b7-h3 compounds and methods of use
WO2024100455A1 (en) * 2022-11-07 2024-05-16 argenx BV Methods for treating primary membranous nephropathy using fcrn antagonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602977B1 (en) * 1999-04-19 2003-08-05 Biovitrum Ab Receptor structures
US20100266530A1 (en) * 2005-04-29 2010-10-21 The Jackson Laboratory FcRN ANTIBODIES AND USES THEREOF
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
CN101421297A (zh) * 2006-02-17 2009-04-29 森托尼克斯制药有限公司 阻断lgG对FcRn的结合的肽
JP5718638B2 (ja) 2007-07-31 2015-05-13 アフィボディ・アーベー 新規な組成物、方法および使用
MX2010001363A (es) * 2007-08-09 2010-03-09 Syntonix Pharmaceuticals Inc Peptidos inmunomoduladores.
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
CA3131470A1 (en) 2008-04-25 2009-10-29 Takeda Pharmaceutical Company Limited Fc receptor binding proteins
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
JP5960598B2 (ja) * 2009-11-04 2016-08-02 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
EP2933262B1 (en) 2010-07-09 2018-05-02 Affibody AB Polypeptides
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
CN103379915A (zh) * 2011-02-15 2013-10-30 米迪缪尼有限公司 Hsa相关组合物及使用方法
DK2912054T3 (en) 2012-10-25 2017-09-11 Affibody Ab Albumin-binding polypeptide
BR112015021730A2 (pt) 2013-03-15 2017-08-29 Affibody Ab POLIPEPTÍDEO DE LIGAÇÃO AO FcRn, PROTEÍNA DE FUSÃO OU CONJUGADO, POLINUCLEOTÍDEO QUE CODIFICA UM POLIPEPTÍDEO, COMPOSIÇÃO, POLIPEPTÍDEO DE LIGAÇÃO AO FcRn, PROTEÍNA DE FUSÃO OU CONJUGADO E POLIPEPTÍDEO DE LIGAÇÃO AO FcRn, PROTEÍNA DE FUSÃO, CONJUGADO OU COMPOSIÇÃO PARA USO
LT3039033T (lt) 2013-08-28 2019-10-25 Affibody Ab Surišantys polipeptidai, turintys mutuotą karkasą
MX2017003459A (es) 2014-09-17 2017-10-31 Affibody Ab Polipeptidos novedosos.

Also Published As

Publication number Publication date
JP2016511280A (ja) 2016-04-14
ES2660912T3 (es) 2018-03-26
CA2902657A1 (en) 2014-09-18
RU2681428C2 (ru) 2019-03-06
CN105209482B (zh) 2022-04-29
US20180118807A1 (en) 2018-05-03
LT2970406T (lt) 2018-03-12
AU2014230018A1 (en) 2015-11-05
IL240606B (en) 2020-05-31
MY171407A (en) 2019-10-11
US9975943B2 (en) 2018-05-22
WO2014140366A1 (en) 2014-09-18
KR102191654B1 (ko) 2020-12-16
HK1216756A1 (zh) 2016-12-02
RU2015141224A (ru) 2017-04-21
EP2970406B1 (en) 2017-12-13
CN105209482A (zh) 2015-12-30
BR112015021730A2 (pt) 2017-08-29
IL240606A0 (en) 2015-09-24
MX366425B (es) 2019-07-04
JP6608288B2 (ja) 2019-11-20
US20200199197A1 (en) 2020-06-25
EP2970406A1 (en) 2016-01-20
KR20150132349A (ko) 2015-11-25
AU2014230018B2 (en) 2018-02-22
DK2970406T3 (en) 2018-02-05
CA2902657C (en) 2022-05-10
US10562955B2 (en) 2020-02-18
US20160031967A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
MY171407A (en) New polypeptides
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
SI3265478T1 (sl) Fuzijski proteini, ki obsegajo vezavni protein in polipeptid interlevkin-15, ki ima zmanjšano afiniteto za IL15RA, in terapevtske uporabe le-teh
MX2015011951A (es) Proteinas de fusion que comprenden partes de union a pdgf y vegf y metodos de uso de las mismas.
HK1223017A1 (zh) 具有降低的受體介導的清除率的生物活性多肽單體-免疫球蛋白 片段綴合物，及其製備方法
MX2016000611A (es) Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.
WO2015063611A3 (en) Albumin variants and uses thereof
PH12014502767A1 (en) Interleukin-2 fusion proteins and uses thereof
NZ722055A (en) Fcrn antagonists and methods of use
WO2013184939A3 (en) Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
IL223989B (en) Albumin binding polypeptide, fusion protein or conjugate comprising said polypeptide, polynucleotide encoding said albumin binding polypeptide and various aspects related thereto
MX2015011350A (es) Proteinas de fusion de apelina y usos de estas.
PH12016500123A1 (en) Therapeutic fusion protein
WO2013177398A3 (en) Non-natural consensus albumin binding domains
HK1244016A1 (zh) FC融合高親和力IGE受體α鏈
PH12016500111A1 (en) An immunoglobulin fc conjugate which maintains binding affinity of immunoglobulin fc fragment to fcrn
MY188784A (en) Il-17a-binding polypeptides
HK1221163A1 (zh) 融合多肽的替代配方
EP2969009A4 (en) MODIFIED FC FUSION PROTEINS
MX2017003459A (es) Polipeptidos novedosos.
PH12015501854A1 (en) Factor ix polypeptide formulations
SG11201505800RA (en) Recombinant yeast transformant and process for preparing immunoglobulin fc fragment employing the same

Legal Events

Date Code Title Description
FG Grant or registration